Acme United CorpACU

Acme United Corp’s second-quarter press release is the corporate equivalent of a holiday sales banner: revenue up 16% year-over-year to $62.7 million for the three months ending June 30, 2026, driven in part by its My Medic tactical-products unit and an 8% rebound in Westcott cutting tools. The headline is real, the growth is measurable, and the newsroom cheerleaders have done their job. What the press release doesn’t say is how much of that revenue actually drops to the bottom line, or whether the seasonal My Medic bump will survive the autumn slowdown.

Acme sells scissors, rulers, trauma kits, and office essentials through Westcott and other brands, and the company’s filing history shows a business that is steadily rebuilding after pandemic disruptions. Its filing index reveals a company that still files Forms 10-Q and 8-K with the same diligence as a student cramming for finals, which is reassuring but not transformative. The latest 10-Q for the quarter ending March 31, 2026, shows $52.3 million in revenue, $985,000 in net income, $1.7 million in operating income, and a cash position of $4.2 million against $63.4 million in inventory. The cash-to-inventory ratio is 0.07, a figure that would make any CFO reach for the antacids.

Acme’s board approved a new $100 million credit facility with HSBC Bank USA, N.A., on July 15, 2026, priced at SOFR plus a margin and subject to quarterly covenants on leverage and liquidity. The agreement is a vote of confidence from a bank, not a vote of confidence from the market, and it arrives just as the company’s operating cash flow turned negative to the tune of $2.2 million in Q1 2026. The filing also reveals that the company’s diluted EPS for the quarter was $0.24, and its weighted average diluted share count was 4.2 million shares, numbers that look modest until you notice that the share count has crept up from earlier quarters and dilution is still on the menu.

The July 23, 2026 press release highlights the My Medic acquisition’s contribution to sales, but the 8-Ks filed on July 21 and July 23, 2026, are light on operational detail, and the ownership XML from July 24, 2026, shows no dramatic insider trades or blockbuster buybacks-just the usual slow bleed of form-filing compliance. The SEC submissions JSON for CIK 0000002098 confirms the filing cadence, while the Company Facts JSON confirms the data points already quoted. There is no chart rail supplied in the evidence, so any trading levels or chart analysis would be pure invention.

What changed this week: the credit line is new, the My Medic sales uplift is measurable, and the inventory build continues unabated. What remains unproven: whether the sales momentum can translate into durable earnings, whether the credit facility will be drawn, and whether dilution will stay within investor tolerance. The next meaningful milestone would be the 10-Q for the quarter ending June 30, 2026, expected to show whether the My Medic bump was a one-off or the start of a new chapter.